Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital hea
Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year